3 US Penny Stocks With At Least $80M Market Cap

In This Article:

As the United States market experiences a tech rally led by chip stocks, with indices like the S&P 500 and Nasdaq showing gains, investors are keenly watching for opportunities in various segments. Penny stocks, though an older term, continue to represent smaller or less-established companies that might offer significant value. By focusing on those with strong financial fundamentals and potential growth trajectories, investors can uncover promising opportunities among these often-overlooked stocks.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.80

$5.97M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.22

$1.76B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$102.23M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.90

$10.89M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.3021

$12.01M

★★★★★★

North European Oil Royalty Trust (NYSE:NRT)

$4.755

$43.66M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.77

$47.54M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.86

$24.83M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.04

$88.55M

★★★★★☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Highest Performances Holdings

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Highest Performances Holdings Inc. provides financial technology services in China and has a market cap of $88.51 million.

Operations: The company generates CN¥2.09 billion from its distribution and management of wealth management services segment.

Market Cap: $88.51M

Highest Performances Holdings Inc., with a market cap of US$88.51 million, faces challenges despite generating CN¥2.09 billion in revenue from its wealth management services. The company is unprofitable and has seen increased losses over the past five years. It recently received a Nasdaq notification for non-compliance with the minimum bid price requirement, providing until May 2025 to rectify this or risk delisting. While it maintains a stable cash runway exceeding three years, its board lacks experience and recent executive changes may impact strategic direction. Despite these hurdles, it has not diluted shareholders significantly in the past year.

NasdaqGM:HPH Revenue & Expenses Breakdown as at Jan 2025
NasdaqGM:HPH Revenue & Expenses Breakdown as at Jan 2025

MacroGenics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MacroGenics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing antibody-based cancer therapeutics in the United States, with a market cap of $217.16 million.